Last 12 months
Inside the activity.
0 purchase rows · 46 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 7 |
| Dec 2025 | 0 | 9 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 15 |
| Aug 2026 | 0 | 5 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 10, 2022 Filed Feb 14, 2022 22:23 UTC |
BAKER BROS. ADVISORS LPDirector · 10% owner
667, L.P.Director · 10% owner
BAKER JULIANDirector · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
BAKER FELIXDirector · 10% owner
|
PurchaseCommon Stock | 40,164 | $66.57 | $2,673,576.91 |
DisclosureSEC source: 0001209191-22-009411 · doc4.xml · nonDerivative · entry 5 BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner 667, L.P. · CIK 0001551139 · Director · 10% owner BAKER JULIAN · CIK 0001087939 · Director · 10% owner Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner BAKER FELIX · CIK 0001087940 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 30,973,279 F10 · price: The price reported in Column 4 is a weighted average price. These shares of Common Stock of the Issuer were traded by Life Sciences in multiple transactions at prices ranging from $66.43 to $66.77, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Staff"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote. F5 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the ''Adviser GP'') is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. F6 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose. F7 · ownership.nature: Includes beneficial ownership of 7,233 shares of Common Stock previously issued to Julian C. Baker pursuant to the Stock Incentive Plan in lieu of director retainer fees, 4,725 shares of Common Stock, 2,802 of which were received previously from vested restricted stock units (each an "RSU") and 175,000 shares of Common Stock received previously from exercise of 175,000 non-qualified stock options to purchase Common Stock of the Issuer ("Stock Options") that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the Funds may be deemed to own a portion. F8 · ownership.nature: Pursuant to agreements between Julian C. Baker and the Adviser and the policies of the Adviser, the Adviser has voting and dispositive power over the Common Stock received in lieu of director retainer fees, Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs. F9 · ownership.nature: Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued in lieu of director retainer fees and the Funds are entitled to an indirect proportionate pecuniary interest in the securities. The Funds each own an indirect proportionate pecuniary interest in the shares of Common Stock. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock issued in lieu of director retainer fees, Stock Options, Common Stock issued upon exercise of Stock Options, RSU's payable solely in Common Stock and Common Stock received upon vesting of RSUs (ie. no direct pecuniary interest). F11 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 21:25 UTC |
Dickinson Jonathan ElliottEVP, General Manager, Europe
|
SaleCommon Stock | 7,375 | $74.19 | $547,151.25 |
DisclosureSEC source: 0001209191-22-006373 · doc4.xml · nonDerivative · entry 1 Dickinson Jonathan Elliott · CIK 0001780561 · EVP, General Manager, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,214 F1 · price: Reporting person undertakes to provide upon request by Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F2 · price: Represents weighted average sale price. Actual sale prices ranged from $73.61 to $74.57 F3 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F4 · balance_after: Includes an aggregate of 19,705 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 24, 2022 Filed Jan 26, 2022 21:11 UTC |
Morrissey Michael JamesEVP, Head of Tech. Operations
|
Tax withholdingCommon Stock | 78 | $75.34 | $5,876.52 |
DisclosureSEC source: 0001209191-22-005057 · doc4.xml · nonDerivative · entry 1 Morrissey Michael James · CIK 0001780915 · EVP, Head of Tech. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,610 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 31,227 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 24, 2022 Filed Jan 26, 2022 21:09 UTC |
Dickinson Jonathan ElliottEVP, General Manager, Europe
|
Tax withholdingCommon Stock | 78 | $75.34 | $5,876.52 |
DisclosureSEC source: 0001209191-22-005051 · doc4.xml · nonDerivative · entry 1 Dickinson Jonathan Elliott · CIK 0001780561 · EVP, General Manager, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,589 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 19,705 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 19, 2022 Filed Jan 20, 2022 21:21 UTC |
Morrissey Michael JamesEVP, Head of Tech. Operations
|
GrantCommon Stock | 6,959 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-004039 · doc4.xml · nonDerivative · entry 3 Morrissey Michael James · CIK 0001780915 · EVP, Head of Tech. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,688 F2 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Mr. Morrissey's continued service with the Issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. F3 · balance_after: Including the January 19, 2022 Restricted Stock Unit Grant, this includes an aggregate of 32,337 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 19, 2022 Filed Jan 20, 2022 21:18 UTC |
Dickinson Jonathan ElliottEVP, General Manager, Europe
|
GrantCommon Stock | 6,959 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-004036 · doc4.xml · nonDerivative · entry 3 Dickinson Jonathan Elliott · CIK 0001780561 · EVP, General Manager, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,667 F2 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Mr. Dickinson's continued service with the Issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. F3 · balance_after: Including the January 19, 2022 Restricted Stock Unit Grant, this includes an aggregate of 20,815 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 21:37 UTC |
Trower PaulPrincipal Accounting Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 3,250 | $0.00 Strike: $74.78 | $0.00 |
DisclosureSEC source: 0001209191-22-004450 · doc4.xml · derivative · entry 1 Trower Paul · CIK 0001642041 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,250 Underlying: Common Stock · 3,250 shares Expires 2032-01-18 F1 · derivative.exercise_date: Beginning January 19, 2022, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2022 and the remainder vesting monthly over three years. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 21:25 UTC |
SWAIN PAULA JEVP, Human Resources
|
GrantEmployee Stock Option (right to buy) · Derivative | 15,054 | $0.00 Strike: $74.78 | $0.00 |
DisclosureSEC source: 0001209191-22-004434 · doc4.xml · derivative · entry 1 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,054 Underlying: Common Stock · 15,054 shares Expires 2032-01-18 F1 · derivative.exercise_date: Beginning January 19, 2022, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2022 and the remainder vesting monthly over three years. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 21:24 UTC |
Stein Steven HEVP & Chief Medical Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 15,054 | $0.00 Strike: $74.78 | $0.00 |
DisclosureSEC source: 0001209191-22-004429 · doc4.xml · derivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,054 Underlying: Common Stock · 15,054 shares Expires 2032-01-18 F1 · derivative.exercise_date: Beginning January 19, 2022, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2022 and the remainder vesting monthly over three years. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 21:22 UTC |
Stamoulis ChristianaEVP & Chief Financial Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 15,054 | $0.00 Strike: $74.78 | $0.00 |
DisclosureSEC source: 0001209191-22-004425 · doc4.xml · derivative · entry 1 Stamoulis Christiana · CIK 0001502917 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,054 Underlying: Common Stock · 15,054 shares Expires 2032-01-18 F1 · derivative.exercise_date: Beginning January 19, 2022, options become exercisable in 37 installments, with the first 25% vesting on July 2, 2022 and the remainder vesting monthly over three years. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 21:20 UTC |
Pasquale Maria EEVP & General Counsel
|
GrantEmployee Stock Option (right to buy) · Derivative | 15,054 | $0.00 Strike: $74.78 | $0.00 |
DisclosureSEC source: 0001209191-22-004421 · doc4.xml · derivative · entry 1 Pasquale Maria E · CIK 0001736295 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,054 Underlying: Common Stock · 15,054 shares Expires 2032-01-18 F1 · derivative.exercise_date: Beginning January 19, 2022, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2022 and the remainder vesting monthly over three years. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 21:18 UTC |
Iyengar Vijay KEVP GPS, BD, & Licensing
|
GrantEmployee Stock Option (right to buy) · Derivative | 15,054 | $0.00 Strike: $74.78 | $0.00 |
DisclosureSEC source: 0001209191-22-004417 · doc4.xml · derivative · entry 1 Iyengar Vijay K · CIK 0001670000 · EVP GPS, BD, & Licensing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,054 Underlying: Common Stock · 15,054 shares Expires 2032-01-18 F1 · derivative.exercise_date: Beginning January 19, 2022, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2022 and the remainder vesting monthly over three years. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 21:16 UTC |
Hoppenot HerveDirector · Chairman / CEO · President
|
GrantEmployee Stock Option (right to buy) · Derivative | 84,852 | $0.00 Strike: $74.78 | $0.00 |
DisclosureSEC source: 0001209191-22-004404 · doc4.xml · derivative · entry 1 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,852 Underlying: Common Stock · 84,852 shares Expires 2032-01-18 F1 · derivative.exercise_date: Beginning January 19, 2022, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2022 and the remainder vesting monthly over three years. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 21:14 UTC |
Flannelly Barry PEVP & General Manager US
|
GrantEmployee Stock Option (right to buy) · Derivative | 15,054 | $0.00 Strike: $74.78 | $0.00 |
DisclosureSEC source: 0001209191-22-004400 · doc4.xml · derivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,054 Underlying: Common Stock · 15,054 shares Expires 2032-01-18 F1 · derivative.exercise_date: Beginning January 19, 2022, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2022 and the remainder vesting monthly over three years. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 21:13 UTC |
Dhanak DashyantEVP & Chief Scientific Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 15,054 | $0.00 Strike: $74.78 | $0.00 |
DisclosureSEC source: 0001209191-22-004398 · doc4.xml · derivative · entry 1 Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,054 Underlying: Common Stock · 15,054 shares Expires 2032-01-18 F1 · derivative.exercise_date: Beginning January 19, 2022, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2022 and the remainder vesting monthly over three years. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 21:21 UTC |
Morrissey Michael JamesEVP, Head of Tech. Operations
|
Tax withholdingCommon Stock | 101 | $75.01 | $7,576.01 |
DisclosureSEC source: 0001209191-22-004039 · doc4.xml · nonDerivative · entry 2 Morrissey Michael James · CIK 0001780915 · EVP, Head of Tech. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,729 Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 21:21 UTC |
Morrissey Michael JamesEVP, Head of Tech. Operations
|
Tax withholdingCommon Stock | 101 | $75.01 | $7,576.01 |
DisclosureSEC source: 0001209191-22-004039 · doc4.xml · nonDerivative · entry 1 Morrissey Michael James · CIK 0001780915 · EVP, Head of Tech. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,830 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 21:18 UTC |
Dickinson Jonathan ElliottEVP, General Manager, Europe
|
Tax withholdingCommon Stock | 101 | $75.01 | $7,576.01 |
DisclosureSEC source: 0001209191-22-004036 · doc4.xml · nonDerivative · entry 2 Dickinson Jonathan Elliott · CIK 0001780561 · EVP, General Manager, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,708 Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 21:18 UTC |
Dickinson Jonathan ElliottEVP, General Manager, Europe
|
Tax withholdingCommon Stock | 101 | $75.01 | $7,576.01 |
DisclosureSEC source: 0001209191-22-004036 · doc4.xml · nonDerivative · entry 1 Dickinson Jonathan Elliott · CIK 0001780561 · EVP, General Manager, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,809 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:18 UTC |
SWAIN PAULA JEVP, Human Resources
|
Exercise / conversionNon Qualfied Stock Option (right to buy) · Derivative | 10,870 | $0.00 Strike: $73.21 | $0.00 |
DisclosureSEC source: 0001209191-22-002853 · doc4.xml · derivative · entry 3 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,870 shares Expires 2022-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning January 8, 2015, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:18 UTC |
SWAIN PAULA JEVP, Human Resources
|
SaleCommon Stock | 10,870 | $73.31 | $796,879.70 |
DisclosureSEC source: 0001209191-22-002853 · doc4.xml · nonDerivative · entry 2 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,371 F2 · balance_after: Includes an aggregate of 33,663 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:18 UTC |
SWAIN PAULA JEVP, Human Resources
|
Exercise / conversionCommon Stock | 10,870 | $73.21 | $795,792.70 |
DisclosureSEC source: 0001209191-22-002853 · doc4.xml · nonDerivative · entry 1 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,241 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. Read SEC document |
| January 04, 2022 Filed Jan 5, 2022 21:25 UTC |
SWAIN PAULA JEVP, Human Resources
|
Exercise / conversionNon Qualfied Stock Option (right to buy) · Derivative | 9,319 | $0.00 Strike: $73.21 | $0.00 |
DisclosureSEC source: 0001209191-22-001688 · doc4.xml · derivative · entry 4 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,870 Underlying: Common Stock · 9,319 shares Expires 2022-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Beginning January 8, 2015, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. Read SEC document |
| January 04, 2022 Filed Jan 5, 2022 21:25 UTC |
SWAIN PAULA JEVP, Human Resources
|
SaleCommon Stock | 9,319 | $73.46 | $684,573.74 |
DisclosureSEC source: 0001209191-22-001688 · doc4.xml · nonDerivative · entry 3 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,371 F3 · price: Represents weighted average sale price. Actual sale prices ranged from $73.31 - $73.73. Reporting person undertakes to provide upon request by Securities and Exchange Commission, the issuer or a security holder of the issuer detailed information regarding the price and number of shares sold within range indicated. F4 · balance_after: Includes an aggregate of 33,663 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 04, 2022 Filed Jan 5, 2022 21:25 UTC |
SWAIN PAULA JEVP, Human Resources
|
Exercise / conversionCommon Stock | 9,319 | $73.21 | $682,243.99 |
DisclosureSEC source: 0001209191-22-001688 · doc4.xml · nonDerivative · entry 2 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,690 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 21:26 UTC |
Dickinson Jonathan ElliottEVP, General Manager, Europe
|
Tax withholdingCommon Stock | 136 | $71.81 | $9,766.16 |
DisclosureSEC source: 0001209191-22-002190 · doc4.xml · nonDerivative · entry 1 Dickinson Jonathan Elliott · CIK 0001780561 · EVP, General Manager, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,910 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of resticted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 16,731 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 21:28 UTC |
Morrissey Michael JamesEVP, Head of Tech. Operations
|
Tax withholdingCommon Stock | 136 | $71.81 | $9,766.16 |
DisclosureSEC source: 0001209191-22-002192 · doc4.xml · nonDerivative · entry 1 Morrissey Michael James · CIK 0001780915 · EVP, Head of Tech. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,931 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of resticted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 28,253 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:40 UTC |
Trower PaulPrincipal Accounting Officer
|
Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 1,396 | $0.00 Strike: $73.21 | $0.00 |
DisclosureSEC source: 0001209191-22-001736 · doc4.xml · derivative · entry 6 Trower Paul · CIK 0001642041 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,396 shares Expires 2022-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning January 8, 2015, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:40 UTC |
Trower PaulPrincipal Accounting Officer
|
Exercise / conversionNon- Qualified Stock Option (right to buy) · Derivative | 6,818 | $0.00 Strike: $73.21 | $0.00 |
DisclosureSEC source: 0001209191-22-001736 · doc4.xml · derivative · entry 5 Trower Paul · CIK 0001642041 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,818 shares Expires 2022-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning January 8, 2015, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:40 UTC |
Trower PaulPrincipal Accounting Officer
|
SaleCommon Stock | 1,396 | $73.31 | $102,340.76 |
DisclosureSEC source: 0001209191-22-001736 · doc4.xml · nonDerivative · entry 4 Trower Paul · CIK 0001642041 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,268 F2 · balance_after: Includes an aggregate of 17,780 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:40 UTC |
Trower PaulPrincipal Accounting Officer
|
Exercise / conversionCommon Stock | 1,396 | $73.21 | $102,201.16 |
DisclosureSEC source: 0001209191-22-001736 · doc4.xml · nonDerivative · entry 3 Trower Paul · CIK 0001642041 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,664 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:40 UTC |
Trower PaulPrincipal Accounting Officer
|
SaleCommon Stock | 6,818 | $73.31 | $499,827.58 |
DisclosureSEC source: 0001209191-22-001736 · doc4.xml · nonDerivative · entry 2 Trower Paul · CIK 0001642041 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,268 Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:40 UTC |
Trower PaulPrincipal Accounting Officer
|
Exercise / conversionCommon Stock | 6,818 | $73.21 | $499,145.78 |
DisclosureSEC source: 0001209191-22-001736 · doc4.xml · nonDerivative · entry 1 Trower Paul · CIK 0001642041 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,086 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. Read SEC document |
| January 01, 2022 Filed Jan 5, 2022 21:21 UTC |
Stein Steven HEVP & Chief Medical Officer
|
GrantCommon Stock | 28,926 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-001670 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,823 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 100% on December 31, 2025, subject to Steven Stein's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Includes an aggregate of 101,955 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 01, 2022 Filed Jan 5, 2022 21:19 UTC |
Stamoulis ChristianaEVP & Chief Financial Officer
|
GrantCommon Stock | 14,463 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-001661 · doc4.xml · nonDerivative · entry 1 Stamoulis Christiana · CIK 0001502917 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,462 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 100% on December 31, 2025, subject to Christiana Stamoulis's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Includes an aggregate of 51,144 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 01, 2022 Filed Jan 5, 2022 21:25 UTC |
SWAIN PAULA JEVP, Human Resources
|
GrantCommon Stock | 8,678 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-001688 · doc4.xml · nonDerivative · entry 1 SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,371 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 100% on December 31, 2025, subject to Paula Swain's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| January 01, 2022 Filed Jan 5, 2022 21:17 UTC |
Pasquale Maria EEVP & General Counsel
|
GrantCommon Stock | 14,463 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-001656 · doc4.xml · nonDerivative · entry 1 Pasquale Maria E · CIK 0001736295 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,575 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 100% on December 31, 2025, subject to Maria Pasquale's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Includes an aggregate of 40,930 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 01, 2022 Filed Jan 5, 2022 21:13 UTC |
Morrissey Michael JamesEVP, Head of Tech. Operations
|
GrantCommon Stock | 3,615 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-001645 · doc4.xml · nonDerivative · entry 1 Morrissey Michael James · CIK 0001780915 · EVP, Head of Tech. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,067 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 100% on December 31, 2025, subject to Michael Morrissey's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Includes an aggregate of 30,192 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 01, 2022 Filed Jan 5, 2022 21:12 UTC |
Iyengar Vijay KEVP GPS, BD, & Licensing
|
GrantCommon Stock | 8,678 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-001643 · doc4.xml · nonDerivative · entry 1 Iyengar Vijay K · CIK 0001670000 · EVP GPS, BD, & Licensing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,417 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 100% on December 31, 2025, subject to Vijay Iyengar's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Includes an aggregate of 33,663 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 01, 2022 Filed Jan 5, 2022 21:10 UTC |
Flannelly Barry PEVP & General Manager US
|
GrantCommon Stock | 8,678 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-001641 · doc4.xml · nonDerivative · entry 1 Flannelly Barry P · CIK 0001615842 · EVP & General Manager US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,292 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 100% on December 31, 2025, subject to Barry Flannelly's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Includes an aggregate of 56,667 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 01, 2022 Filed Jan 5, 2022 21:08 UTC |
Dickinson Jonathan ElliottEVP, General Manager, Europe
|
GrantCommon Stock | 3,615 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-001637 · doc4.xml · nonDerivative · entry 1 Dickinson Jonathan Elliott · CIK 0001780561 · EVP, General Manager, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,046 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 100% on December 31, 2025, subject to Jonathan Dickinson's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: This includes an aggregate of 18,670 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| January 01, 2022 Filed Jan 5, 2022 21:06 UTC |
Dhanak DashyantEVP & Chief Scientific Officer
|
GrantCommon Stock | 8,678 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-001631 · doc4.xml · nonDerivative · entry 1 Dhanak Dashyant · CIK 0001760682 · EVP & Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,142 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 100% on December 31, 2025, subject to Dashyant Dhanak's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Includes an aggregate of 34,035 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 21:15 UTC |
DIXON WENDY LDirector
|
GrantCommon Stock | 260 | $73.40 | $19,084.00 |
DisclosureSEC source: 0001209191-22-000697 · doc4.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,519 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,923 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 21:16 UTC |
BAKER BROS. ADVISORS LPDirector · 10% owner
667, L.P.Director · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector · 10% owner
|
GrantCommon Stock | 419 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-000198 · form4-01042022_010133.xml · nonDerivative · entry 2 BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner 667, L.P. · CIK 0001551139 · Director · 10% owner Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner BAKER FELIX · CIK 0001087940 · Director · 10% owner BAKER JULIAN · CIK 0001087939 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 30,933,115 F1 · price: 419 shares of common stock ("Common Stock") of Incyte Corporation (the "Issuer") issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of quarterly director retainer fees of $29,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's board of directors (the "Board") as a representative of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). F1 · ownership.nature: 419 shares of common stock ("Common Stock") of Incyte Corporation (the "Issuer") issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of quarterly director retainer fees of $29,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's board of directors (the "Board") as a representative of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). F2 · ownership.nature: Pursuant to the policies of Baker Bros. Advisors LP (the "Adviser"), Julian C. Baker does not have a right to any of the Issuer's securities issued in lieu of director retainer fees and the Funds are entitled to an indirect proportionate pecuniary interest in the securities. The Funds each own an indirect proportionate pecuniary interest in the shares of Common Stock. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock issued in lieu of director retainer fees, the non-qualified stock options ("Stock Options"), Common Stock issued upon exercise of Stock Options, restricted stock units (each an "RSU") payable solely in Common Stock and Common Stock received upon vesting of RSUs (ie. no direct pecuniary interest). F4 · ownership.nature: Includes beneficial ownership of 6,814 shares of Common Stock previously issued to Julian C. Baker pursuant to the Stock Incentive Plan in lieu of director retainer fees, 4,725 shares of Common Stock, 2,802 of which were received previously from vested RSUs and 175,000 shares of Common Stock received previously from exercise of 175,000 Stock Options that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the Funds may be deemed to own a portion. F5 · ownership.nature: The 419 shares are reported for each of the Funds as each has an indirect pecuniary interest. F6 · ownership.nature: The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. F7 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose. F8 · ownership.nature: Pursuant to agreements between Julian C. Baker and the Adviser and the policies of the Adviser, the Adviser has voting and dispositive power over the Common Stock received in lieu of director retainer fees, Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs. F9 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 21:16 UTC |
BAKER BROS. ADVISORS LPDirector · 10% owner
667, L.P.Director · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector · 10% owner
|
GrantCommon Stock | 419 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-000198 · form4-01042022_010133.xml · nonDerivative · entry 1 BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner 667, L.P. · CIK 0001551139 · Director · 10% owner Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner BAKER FELIX · CIK 0001087940 · Director · 10% owner BAKER JULIAN · CIK 0001087939 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 2,873,829 F1 · price: 419 shares of common stock ("Common Stock") of Incyte Corporation (the "Issuer") issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of quarterly director retainer fees of $29,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's board of directors (the "Board") as a representative of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). F1 · ownership.nature: 419 shares of common stock ("Common Stock") of Incyte Corporation (the "Issuer") issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of quarterly director retainer fees of $29,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's board of directors (the "Board") as a representative of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). F2 · ownership.nature: Pursuant to the policies of Baker Bros. Advisors LP (the "Adviser"), Julian C. Baker does not have a right to any of the Issuer's securities issued in lieu of director retainer fees and the Funds are entitled to an indirect proportionate pecuniary interest in the securities. The Funds each own an indirect proportionate pecuniary interest in the shares of Common Stock. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock issued in lieu of director retainer fees, the non-qualified stock options ("Stock Options"), Common Stock issued upon exercise of Stock Options, restricted stock units (each an "RSU") payable solely in Common Stock and Common Stock received upon vesting of RSUs (ie. no direct pecuniary interest). F3 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP),LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667. F4 · ownership.nature: Includes beneficial ownership of 6,814 shares of Common Stock previously issued to Julian C. Baker pursuant to the Stock Incentive Plan in lieu of director retainer fees, 4,725 shares of Common Stock, 2,802 of which were received previously from vested RSUs and 175,000 shares of Common Stock received previously from exercise of 175,000 Stock Options that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the Funds may be deemed to own a portion. F5 · ownership.nature: The 419 shares are reported for each of the Funds as each has an indirect pecuniary interest. F6 · ownership.nature: The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. F7 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose. F8 · ownership.nature: Pursuant to agreements between Julian C. Baker and the Adviser and the policies of the Adviser, the Adviser has voting and dispositive power over the Common Stock received in lieu of director retainer fees, Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 21:17 UTC |
HARRIGAN EDMUNDDirector
|
GrantCommon Stock | 253 | $73.40 | $18,570.20 |
DisclosureSEC source: 0001209191-22-000712 · doc4.xml · nonDerivative · entry 1 HARRIGAN EDMUND · CIK 0001177917 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,332 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,923 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 21:16 UTC |
FOUSE JACQUALYN ADirector
|
GrantCommon Stock | 289 | $73.40 | $21,212.60 |
DisclosureSEC source: 0001209191-22-000702 · doc4.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,231 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,923 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 21:14 UTC |
Clancy Paul JDirector
|
GrantCommon Stock | 343 | $73.40 | $25,176.20 |
DisclosureSEC source: 0001209191-22-000690 · doc4.xml · nonDerivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,964 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,923 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| December 23, 2021 Filed Dec 27, 2021 21:11 UTC |
DIXON WENDY LDirector
|
Exercise / conversionNon Qualfied Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $73.25 | $0.00 |
DisclosureSEC source: 0001209191-21-071241 · doc4.xml · derivative · entry 3 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2022-05-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Beginning May 30, 2012, options become exercisable in full on May 30, 2013. Read SEC document |
| December 23, 2021 Filed Dec 27, 2021 21:11 UTC |
DIXON WENDY LDirector
|
SaleCommon Stock | 20,000 | $22.05 | $441,000.00 |
DisclosureSEC source: 0001209191-21-071241 · doc4.xml · nonDerivative · entry 2 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,259 F2 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F3 · balance_after: Includes an aggregate of 1,923 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.